Cargando…
Glucagon-like peptide-1 analogues - an efficient therapeutic option for the severe insulin resistance of lipodystrophic syndromes: two case reports
BACKGROUND: Lipodystrophic syndromes are uncommon medical conditions which are normally associated with metabolic disorders, such as diabetes mellitus, dyslipidemia, and fatty liver disease. These complications are generally difficult to treat, particularly diabetes, due to severe insulin resistance...
Autores principales: | Oliveira, Joana, Lau, Eva, Carvalho, Davide, Freitas, Paula |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237351/ https://www.ncbi.nlm.nih.gov/pubmed/28086952 http://dx.doi.org/10.1186/s13256-016-1175-1 |
Ejemplares similares
-
Glucagon-like peptide-1 analogues: An overview
por: Gupta, Vishal
Publicado: (2013) -
Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity
por: Williams, David M, et al.
Publicado: (2022) -
Lipodystrophic laminopathies: Diagnostic clues
por: Guillín-Amarelle, Cristina, et al.
Publicado: (2018) -
Effects of Glucagon-Like-Peptide-1 Analogue Treatment in Genetic Obesity
por: Welling, Mila Sofie, et al.
Publicado: (2021) -
Potential Roles of Glucagon-Like Peptide-1 and Its Analogues in Dementia Targeting Impaired Insulin Secretion and Neurodegeneration
por: Mehan, Sidharth, et al.
Publicado: (2022)